0001209191-18-028492.txt : 20180508 0001209191-18-028492.hdr.sgml : 20180508 20180508080845 ACCESSION NUMBER: 0001209191-18-028492 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180507 FILED AS OF DATE: 20180508 DATE AS OF CHANGE: 20180508 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Holles Natalie C. CENTRAL INDEX KEY: 0001580111 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37833 FILM NUMBER: 18813026 MAIL ADDRESS: STREET 1: C/O HYPERION THERAPEUTICS, INC. STREET 2: 2000 SIERRA POINT PARKWAY, SUITE 400 CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Audentes Therapeutics, Inc. CENTRAL INDEX KEY: 0001628738 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 461606174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 600 CALIFORNIA ST., 17TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 BUSINESS PHONE: 415-638-6556 MAIL ADDRESS: STREET 1: 600 CALIFORNIA ST., 17TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-05-07 0 0001628738 Audentes Therapeutics, Inc. BOLD 0001580111 Holles Natalie C. C/O AUDENTES THERAPEUTICS, INC. 600 CALIFORNIA STREET, 17TH FLOOR SAN FRANCISCO CA 94108 0 1 0 0 President and COO Stock Option (right to buy) 36.39 2018-05-07 4 A 0 25000 0.00 A 2028-05-07 Common Stock 25000 25000 D The option vests as to 2.0833% of the total shares monthly, beginning June 2, 2018, with 100% of the total shares vested and exercisable on May 2, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. /s/ Thomas Soloway as attorney-in-fact for Natalie Holles 2018-05-08